Effectiveness and safety of colistin: Prospective comparative cohort study

Mical Paul*, Jihad Bishara, Ariela Levcovich, Michal Chowers, Elad Goldberg, Pierre Singer, Shaul Lev, Perla Leon, Maria Raskin, Dafna Yahav, Leonard Leibovici

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Colistin has re-entered clinical use by necessity. We aimed to assess its effectiveness and safety compared with newer antibiotics. Methods: This was a single-centre, prospective cohort study. Inclusion criteria were microbiologically documented pneumonia, urinary tract infection, surgical site infection, meningitis or bacteraemia treated appropriately with colistin versus imipenem, meropenem or ampicillin/sulbactam (comparators). All consecutive patients were included, only once, between May 2006 and July 2009. The primary outcome was 30 day mortality. Multivariable and Cox regression survival analyses were used to adjust comparisons between groups. Odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals are reported. Results: Two hundred patients treated with colistin and 295 patients treated with comparators were included. Treatment with colistin was associated with older age, admission from healthcare facilities, mechanical ventilation and lower rate of early appropriate antibiotic treatment. The 30 day mortality was 39% (78/200) for colistin versus 28.8% (85/295) for comparators; unadjusted OR 1.58 (1.08-2.31). In the adjusted analysis the OR was 1.44 (0.91-2.26) overall and 1.99 (1.06-3.77) for bacteraemic patients (n=220). At the end of follow-up, treatment with colistin was significantly associated with cumulative mortality; adjusted HR 1.27 (1.01-1.60) overall and 1.65 (1.18-2.31) among patients with bacteraemia. Nephrotoxicity at the end of treatment was more frequent with colistin; OR adjusted for other risk factors for nephrotoxicity 3.31 (1.54-7.08). Treatment with colistin was followed by increased incidence of Proteus spp. infections during a 3 month follow-up. Conclusions: The need for colistin treatment is associated with poorer survival. Adjusted analyses suggest that colistin is less effective and more toxic than β-lactam antibiotics.

Original languageEnglish
Article numberdkq069
Pages (from-to)1019-1027
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume65
Issue number5
DOIs
StatePublished - 18 Mar 2010

Keywords

  • Acinetobacter
  • Hospital-acquired infections
  • Klebsiella
  • Multidrug-resistant Gram-negative bacteria
  • Polymyxin

Fingerprint

Dive into the research topics of 'Effectiveness and safety of colistin: Prospective comparative cohort study'. Together they form a unique fingerprint.

Cite this